Statin Therapy Cuts Cardiovascular Risk in HIV Patients, Study Finds

A phase 3 trial named REPRIEVE suggests that daily pitavastatin calcium can lead to a 35% relative reduction in major adverse cardiovascular events in patients with HIV receiving antiretroviral therapy. The trial, which enrolled a global sample, highlights the importance of cardiovascular disease prevention in HIV patients.